Is the GLP-1 era forcing a marketing reset for FMCG brands?

The article focuses on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 drugs) on India’s food and fast-moving consumer goods (FMCG) sectors following regulatory actions by the Drug Controller General of India to curb unauthorized use and misleading promotions. With the recent patent expiry of semaglutide, a key GLP-1 drug ingredient, lower-cost generics have increased accessibility, primarily among affluent urban consumers, prompting shifts in consumption patterns toward more intentional, nutrient-dense, and portion-controlled foods. Industry experts note that this evolving consumer behavior challenges traditional FMCG marketing strategies based on frequent and impulse purchases, urging brands to emphasize health benefits, ingredient transparency, and smaller portions. The government’s regulatory scrutiny underscores concerns about unsupervised use, while food companies like Nestlé and General Mills are already adapting by targeting GLP-1 users with specialized products. Overall, the rise of GLP-1 drugs is seen as accelerating a structural shift toward conscious consumption in India’s food market. [Extracted from the article]